ClinicalTrials.Veeva

Menu

Dextenza in Pterygium Surgery

M

Michelle Rhee MD

Status and phase

Completed
Phase 4

Conditions

Pterygium

Treatments

Drug: Dexamethasone Intracanalicular Insert, 0.4mg
Drug: Prednisolone Acetate 1%

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT04403516
Dextenza in Pterygium Surgery

Details and patient eligibility

About

DEXTENZA for the treatment of post-surgical pain and inflammation compared to standard of care topical prednisolone acetate 1% in patients who undergo pterygium surgery (excision of pterygium with conjunctival autograft)

Full description

In patients who undergo pterygium surgery, eyes will be consecutively assigned to receive either DEXTENZA or topical prednisolone acetate 1%.15 eyes will receive a Dextenza insertion into both the upper and lower puncta at the time of surgery, followed by at postoperative month 1 visit institution of topical prednisolone acetate 1% bid x 2 weeks then qd x 2 weeks then discontinued. 15 eyes will receive starting on postoperative day 1 topical prednisolone acetate 1% q2 hours x 2 weeks then qid for 2 weeks then bid for 2 weeks then qd for 2 weeks then discontinued.

Enrollment

30 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

A patient's study eye must meet the following criteria to be eligible for inclusion in the study:

• Age of at least 18 years with primary pterygia

Exclusion criteria

A patient who meets any of the following criteria will be excluded from the study:

  • Glaucoma
  • Ocular hypertension
  • Prior conjunctival surgery
  • Other uncontrolled ocular disease
  • Ocular surgery in either eye within 3 months
  • Use of eye drops other than postoperative medications and artificial tears

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Single Group Assignment

Masking

None (Open label)

30 participants in 2 patient groups

DEXTENZA Group
Experimental group
Description:
Patients with Pterygium DEXTENZA Group
Treatment:
Drug: Dexamethasone Intracanalicular Insert, 0.4mg
Topical Prednisolone Acetate 1% Group
Experimental group
Description:
Patients with Pterygium Topical Prednisolone Acetate 1% Group
Treatment:
Drug: Prednisolone Acetate 1%

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems